The U.S. pharmaceutical sterility testing market size
is expected to reach USD 713.6 million by 2025, according to a new report by
Grand View Research, Inc. It is anticipated to expand at a CAGR of 11.3% over
the forecast period. Supportive government investment in healthcare industry,
increasing R&D activities, and drug launches are the key factors driving
market growth.
The government is keen on bringing down
healthcare costs which is anticipated to encourage the U.S. Food and Drug
Administration (FDA) to promote fast approvals of generic pharmaceuticals.
Faster approvals drive the need for newer sterility testing methods. This is
anticipated to encourage market participants to spend more on sterility
solutions and in turn, expand the market. With increasing demand for drugs,
companies are launching newer drugs with different routes of administration,
dosage, and indication. These launches require thorough sterility testing and
thus, are anticipated to drive market growth.
On the basis of type, the U.S. pharmaceutical
sterility testing market is segmented into in-house and outsourcing. Most
market players prefer outsourcing sterility testing services, as it is
economically viable. Companies shortlist and select outsourcing firms based on
their experience, expertise, and quality of service. Hence, it is difficult for
new players to enter into this area.
Companies active in the U.S. pharmaceutical
sterility testing market are Charles River Laboratories, Pace Analytical Series
LLC, DynaLabs, Infinity, Boston Analytical, and others. Market players employ
various growth strategies such as mergers, capacity expansion, and venturing
into new regions. For instance, in April 2018, Charles River Labs completed
acquisition of MPI Research, a non-clinical Contract Research Organization
(CRO) providing detailed services to medical device and biopharmaceutical
companies. This acquisition is anticipated to expand biotechnology client base
of the former and to provide the company access to MPI’s scientific expertise
and quality services.
For full research report on U.S.
Pharmaceutical Sterility Testing Market visit here: https://www.grandviewresearch.com/industry-analysis/us-pharmaceutical-sterility-testing-market
Further key
findings from the report suggest:
- U.S. pharmaceutical
sterility testing market was valued at USD 302.2 million in 2017 and is
expected to grow lucratively over the forecast period
- In terms of revenue,
outsourcing segment is anticipated to grow at a lucrative rate during the
forecast period.
- Sterility testing
segment was valued at USD 97.6 million in 2016 and is anticipated to
witness swift growth over the forecast period.
Get free request sample of this report
here : https://www.grandviewresearch.com/industry-analysis/us-pharmaceutical-sterility-testing-market/request/rs1
Grand
View Research has segmented the U.S. pharmaceutical sterility testing market on
the basis of type, test type, end use, and sample:
U.S.
Pharmaceutical Sterility Testing by Type (Revenue, USD Million, 2014 - 2025)
- In-house
- Outsourced
U.S.
Pharmaceutical Sterility Testing by Test Type (Revenue, USD Million, 2014 -
2025)
- Sterility Test
- Bioburden Testing
- Bacterial Endotoxin
Test
U.S.
Pharmaceutical Sterility Testing by End Use (Revenue, USD Million, 2014 - 2025)
- Compounding
Pharmacies
- Medical Device
Companies
- Pharmaceutical
Companies
- Others
U.S.
Pharmaceutical Sterility Testing by Sample (Revenue, USD Million, 2014 - 2025)
- Sterility Drugs
- Medical Devices
- Biologics &
Therapies
About Grand View Research
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
No comments:
Post a Comment